Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009 www.aodhealth.org 1 Featured Article Randomized Controlled Trial of a Brief Intervention for Problematic Prescription Drug Use in Non-Treatment-Seeking Patients Zahradnik A, et al. Addiction. 2009;104(1):109–117. www.aodhealth.org 2 Study Objective • To determine whether brief intervention delivered in general hospitals promotes discontinuation or reduction of problematic prescription drug use. www.aodhealth.org 3 Study Design • Randomized controlled trial of 126 patients admitted to the internal, surgical, or gynecological ward of a general and university hospital in Germany. • Inclusion criteria: – Consumption of prescription drugs (PD) with addiction potential (>60 days within the last 3 months); or – DSM criteria for PD abuse or dependence. • Participants were randomly allocated to either: – 2 motivational-interviewing (MI) sessions (intervention); or – receipt of a booklet about PD generally (control). • Outcomes measured were >25% reduction or discontinuation of daily PD intake. www.aodhealth.org 4 Assessing Validity of an Article about Therapy • Are the results valid? • What are the results? • How can I apply the results to patient care? www.aodhealth.org 5 Are the Results Valid? • Were patients randomized? • Was randomization concealed? • Were patients analyzed in the groups to which they were randomized? • Were patients in the treatment and control groups similar with respect to known prognostic variables? www.aodhealth.org 6 Are the Results Valid? (cont‘d) • Were patients aware of group allocation? • Were clinicians aware of group allocation? • Were outcome assessors aware of group allocation? • Was follow-up complete? www.aodhealth.org 7 Were patients randomized? • Yes. – Patients were randomized by ward. www.aodhealth.org 8 Was randomization concealed? • Unknown. – Data on the method of randomization are not provided. www.aodhealth.org 9 Were patients analyzed in the groups to which they were randomized? • Yes – Outcome measures were analyzed on the basis of intention-to-treat. www.aodhealth.org 10 Were the patients in the treatment and control groups similar? • Yes. – Groups were similar on most demographic and clinical variables. – PD dependence was less common in the control group (35.7%) compared with the intervention group (53.6%) (p=0.049). www.aodhealth.org 11 Were patients aware of group allocation? • Yes. – Patients were aware of group allocation. www.aodhealth.org 12 Were clinicians aware of group allocation? • Yes. – Clinicians were aware of group allocation. www.aodhealth.org 13 Were outcome assessors aware of group allocation? • No. – Follow-up interviews were conducted by staff who had no prior contact with the patient. www.aodhealth.org 14 Was follow-up complete? • Eight patients in the control group (n=70) did not complete follow-up: – 1 had died. – 3 were too ill to answer questions. – 4 could not be contacted. • One patient in the intervention group (n=56) did not complete follow-up: – he or she could not be contacted. www.aodhealth.org 15 What Are the Results? • How large was the treatment effect? • How precise was the estimate of the treatment effect? www.aodhealth.org 16 How large was the treatment effect? Differences in Control Group (CG) and Intervention Group (IG) Prescription Drug use at 3-Month Follow-up All participants CG IG p value Effect size Difference in defined daily dosage* (SD**) 0.26 (2.1) 0.12 (1.4) 0.42 (2.7) 0.08 0.14 Discontinued use (%) 16 (12.7) 6 (8.6) 10 (17.9) 0.17 0.28 Reduced use by >25% (%) 50 (39.7) 21 (30) 29 (51.8) 0.02† 0.45 *Follow-up minus baseline; **standard deviation; †significant (p<0.05). www.aodhealth.org 17 How precise was the estimate of the treatment effect? • The primary hypothesis—that the discontinuation rate would be greater in the intervention group— was not confirmed. • No confidence intervals around the proportion of subjects with >25% reduction in dose were provided. www.aodhealth.org 18 How Can I Apply the Results to Patient Care? • Were the study patients similar to the patients in my practice? • Were all clinically important outcomes considered? • Are the likely treatment benefits worth the potential harm and costs? www.aodhealth.org 19 Were the study patients similar to those in my practice? • Of the final sample, – 61.9% were women. – mean age was 55 years (range, 30–69 years, with 69% age 50 or older). – more than half were married (56.4%). – the majority were retired (69.1%). • The study took place in Germany. • No data on race/ethnicity are provided. www.aodhealth.org 20 Were all clinically important outcomes considered? • No information was provided about the indications for the use of the medications with “addictive potential.” • It is possible that some patients received these medications for pain, anxiety, or insomnia. • Subjective outcomes from the patients were not reported. www.aodhealth.org 21 Are the likely treatment benefits worth the potential harm and costs? • This is not clear due to the lack of information about the prescribed medications, their indications, and patients’ subjective experiences. www.aodhealth.org 22